
|Articles|September 1, 2003
LEISHMANIASIS DRUG
AEterna Laboratories reported recently the results of a phase III trial evaluating its drug Impavido (miltefosine) for the treatment of cutaneous leishmaniasis, showing that patients taking Impavido had a 220-percent better cure rate compared with those in a placebo group.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Lebrikizumab Enters Late-Stage Testing for Nummular Eczema
2
The Weekly Roundup: January 12-16
3
Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types
4
Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib
5


















